The Discounted Cash Flow (DCF) valuation of CytomX Therapeutics Inc (CTMX) is (9.18) USD. With the latest stock price at 1.18 USD, the upside of CytomX Therapeutics Inc based on DCF is -877.7%.
Note: valuation result may not be accurate due to the company's negative cashflows.
| Range | Selected | |
| WACC / Discount Rate | 6.2% - 7.4% | 6.8% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (20.83) - (5.93) | (9.18) |
| Upside | -1865.3% - -602.7% | -877.7% |